ASBP · Aspire Biopharma Holdings, Inc.
One customer — 15% of revenue (the six months ended June 30, 2026)
“One customer accounted for approximately 15% of the Company’s total revenues during the six months ended June 30, 2026.”
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| — | $6202 | — | — | — | |
| — | $6318 | — | — | — | |
| — | -$116 | — | — | — | |
| — | -1.87% | — | — | — | |
| $838.14K | $923.91K | $144.36K | — | — | |
| $2.07M | $789.83K | $126.09K | — | — | |
| $4.16M | $17.64M | $940.42K | $1.34M | $976.35K | |
| $7.29M | $19.35M | $1.21M | $1.34M | $976.35K | |
| -$7.32M | -$19.35M | -$1.21M | — | — | |
| — | -312016.95% | — | — | — | |
| $9.31M | $8.53M | $97.99K | — | — | |
| — | — | $548.68K | $5.81M | $4.32M | |
| -$3.73M | -$5.13M | -$97.99K | $5.8M | $4.32M | |
| — | -$24.48M | -$1.31M | — | — | |
| — | — | $1013 | — | — | |
| -$11.05M | -$24.48M | -$1.31M | $4.46M | $3.34M | |
| — | -394725.06% | — | — | — | |
| USD/shares | $514.90 | -$16.38 | -$1.90 | — | — |
| shares | — | 1.49M | 689.91K | — | — |
| shares | — | 1.49M | 689.91K | — | — |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2023–FY2024: $298.7M in buybacks.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 208 similar-size Biotechnology companies (of 516 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2025 |
|---|---|
| United States | $6,153 |
| Canada | $30 |
| United Kingdom | $19 |
By Product & Service (USD)
| Component | FY2025 |
|---|---|
| Nutraceutical Products | $6,202 |